RTI Biologics Schedules 2013 First Quarter Earnings and Conference Call for April 25, 2013 Business Wire ALACHUA, Fla. -- April 18, 2013 RTI Biologics Inc. (RTI) (Nasdaq:RTIX), a leading provider of orthopedic and other biologic implants, announced today that it plans to release financial results from the first quarter 2013 on Thursday, April 25, 2013 prior to the market open. RTI will host a conference call and simultaneous audio webcast to discuss first quarter 2013 results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call. About RTI Biologics Inc. RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and animal tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries. RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. These processes — BioCleanse®, Tutoplast® and Cancelle® SP DBM — have a combined record of more than four million implants distributed with zero incidence of implant-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality. RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed. Contact: RTI Biologics Inc. Robert Jordheim Chief Financial Officer email@example.com or Jenny Highlander, APR, 386-418-8888 Corporate Communications firstname.lastname@example.org
RTI Biologics Schedules 2013 First Quarter Earnings and Conference Call for April 25, 2013
Press spacebar to pause and continue. Press esc to stop.